Various studies describe increased concentrations of transforming growth factor-13 (TGF-I3) in brain tissue after acute brain injury. However, the role of endogenously pro duced TGF-13 after brain damage to the CNS remains to be
clearly established. Here, the authors examine the influence of TGF-13 produced after an episode of cerebral ischemia by in jecting a soluble TGF-13 type II receptor fused with the Fc region of a human immunoglobulin (TI3RIIs-Fc). First, this molecular constll'ct was characterized as a selective antagonist of TGF-I3. Then, the authors tested its ability to reverse the effect of TGF-13 1 on excitotoxic cell death in murine cortical cell cultures. The addition of 1 j.Lg/mL of TI3RIIs-Fc to the exposure medium antagonized the neuroprotective activity of TGF-13 1 in N-methyl-D-aspartate (NMDA)-induced excitotoxic cell death. These results are consistent with the hypothesis that TGF-13 1 exerts a negative modulatory action on NMDA recep tor-mediated excitotoxicity. To determine the role of TGF-13 1 produced in response to brain damage, the authors used a model of an excitotoxic lesion induced by the intrastriatal injection of 75 nmol of NMDA in the presence of 1.5 j.Lg of TI3RIIs-Fc. The It is well accepted that the toxic overstimulation of postsynaptic glutamate receptors may contribute to pathologic neuronal death resulting from certain acute insults to the CNS, including hypoglycemia, hypoxia ischemia, trauma, and spinal cord injury (Choi et aI., 1992) . Such forms of excitotoxic neuronal death are me-intrastriatal injection of NMDA was demonstrated to induce an early upregulation of the expression of TGF-13 1 mRNA. Fur thermore, when added to the excitotoxin, TI3RIIs-Fc increased (by 2.2-fold, P < 0.05) the lesion size. These observations were strengthened by the fact that an intracortical injection of TI3RIIs-Fc in rats subjected to a 30-minute reversible cerebral focal ischemia aggravated the volume of infarction. In the group injected with the TGF-13 1 antagonist, a 3.5-fold increase was measured in the infarction size (43.3 ± 9.5 versus 152.8 ± 46.3 mm 3 ; P < 0.05). In conclusion, by antagonizing the influ ence of TGF-13 in brain tissue subjected to excitotoxic or isch emic lesion, the authors markedly exacerbated the resulting extent of necrosis. These results suggest that, in response to such insults, brain tissue responds by the synthesis of a neuro protective cytokine, TGF-131, which is involved in the limita tion of the extent of the injury. The pharmacologic potentiation of this endogenous defensive mechanism might represent an alternative and novel strategy for the therapy of hypoxic ischemic cerebral injury. Key Words: TGF-I3-Excitotox icity-Ischemia-Cytokine.
diated by the activation of ion channel-linked glutamate receptors, especially N-methyl-D-aspartate (NMDA) re ceptors (Choi et aI., 1992) , probably because of their high Ca 2 + permeability (Nowak et aI., 1984) . Consider able interest exists for developing effective methods to attenuate excitotoxicity in various disease states. The most direct approach is to administer a pharmacologic compound able to block glutamate-induced responses. Several glutamate antagonists are under development and clinical trial. However, most of these drugs present relatively harmful side effects, which have limited their potential use in humans (Del Zoppo et aI., 1997) . Hence, there is an increasing interest for alternative strategies. Whereas the consequences of the overstimulation of glutamate receptors in the mechanisms that lead to neu ronal death have been studied extensively, little is known about the adaptive responses of brain tissue to limit the extent of such insults. Several studies describe an impor tant increase in cytokine concentrations after cerebral ischemia, as well as various neurologic disorders (review Feuerstein et aI., 1998) . Among these cytokines, trans forming growth factor-� (TGF-�) has elicited an increas ing interest because of its patterns of expression in al tered brain tissue. For example, one study shows an in creased expression of TGF-� I in the brain after ischemic stroke in humans (Krupinski et al., 1996) . Based on this information, TGF-� has been characterized as an injury related cytokine (for review see Krieglstein and Kriegl stein, 1998) .
In vitro, several studies describe a neuroprotective role of TGF-�1 against different metabolic and excitotoxic challenges (Un sicker et al., 1992; Prehn et al., 1993; Klempt et al., 1992) . It also has been reported that, under certain conditions, TGF-� 1 is able to potentiate gluta mate-induced neuronal injury Chao et al., 1992; Prehn and Miller, 1996) . These opposing results may reflect the use of different regi mens of TGF-� treatment, which would induce mUltiple consequences, some protective and some deleterious.
In our laboratory, we demonstrated with a model of primary cortical murine cell cultures that TGF-� 1 fails to influence the survival of neurons when exposed to an apoptotic paradigm but exerts a neuroprotective effect mediated by astrocytes and restricted to NMDA-induced necrosis .
In vivo, several studies describe a marked increase in TGF-� 1 mRNA after hypoxic-ischemic brain injury (Da Cunha et al., 1993; Prehn et al., 1993; Henrich-Noack et al., 1994; McNeill et aI., 1994; Rimaniol et aI., 1995; Vivien et al., 1998) . Whereas the intracerebroventricular application of TGF-� I induces a slight reduction of the ischemic volume McNeill et al., 1994) , there is no clear evidence for the influence of the endogenously produced TGF-�, mainly because of the lack of a potent antagonist.
Transforming growth factor-� elicits its effects through cell surface receptors. Three major types of binding proteins are known to be ubiquitously distributed in TGF-�-responsive cells. They are referred as type I (T�R-I), type II (T�R-II), and type III (betaglycan; T�R III) receptors. Both T�R-I and T�R-II are glycoproteins of 53 and 75 to 85 kDa, respectively, whereas T�R-III is a proteoglycan of 280 to 330 kDa (Massague et aI., 1994) . In the murine brain, TGF-� type I and II receptors are expressed on both neurons and astrocytes (Vivien et aI., 1998) . Molecular cloning and functional analyses show that both T�R-I and T�R-Il are serine/threonine kinase receptors necessary for the signal transduction of TGF-� (Massague et aI., 1994) . The TGF-� type II re ceptor binds to its proper ligand, but the type I receptor requires the presence of bound T�R-II to interact with TGF-� (Wrana et aI., 1992) . After ligand-receptor inter-J Cereb Blood Flow Metab. Vol. 19. No. 12. 1999 action, T�R-I and T�R-Il form a heteromeric complex (Wrana et aI., 1992; Vivien et aI., 1995) , and the T�R-II so bound is able to transphosphorylate T�R-I (Wrana et al., 1992; . Thereafter, the sig naling of TGF-� occurs through the activation of Smad 2/1 and Smad 4 transcriptional factors (Kim et aI., 1997; Dennler et al., 1998) . Because the first step of TGF-� signaling requires an interaction between TGF-� and its type I and type II receptors, we used a molecular con struct made of the extracellular domain of TGF-� type II receptor fused with the Fc region of human immunoglob ulins (Tf3RIIs-Fc). This construct has been characterized as a powerful blocker of the interaction between TGF-� and its cell surface receptors (Komesli et aI., 1998) .
By injecting T�RIls-Fc into brain tissue exposed to an excitotoxic insult or to a reversible cerebral ischemia, we were able to study, for the first time, the role of endog enously produced TGF-�. 
MATERIALS AND METHODS

Materials
Cell culture
Mixed cortical cell cultures containing both neuronal and glial elements were prepared from fetal mice at 15 to 16 days' gestation (Rose et aI., 1993) . Cerebral cortices were dissected and incubated for 20 to 30 minutes in 0.025% of trypsin in media stock (MS; modified Eagle's minimal essential medium with 2 mmollL glutamine and 25 mmollL glucose) and trans ferred to MS supplemented with 5% fetal bovine and 5% horse serum for trituration. Glial cell cultures from cortex were pre pared similarly from 1-to 3-day-01d postnatal pups (Rose et aI., 1993) and plated in MS supplemented with 10% fetal bovine serum and 10% horse serum. Dissociated cortical fetal cells were plated at a density of about 3 x 10 5 cells per well on an established bed of glia in the same plating medium.
All cultures were kept at 37°C in a humidified 5% CO2containing atmosphere. After 3 to 7 days in vitro, glial division was halted by exposure to 10 fLmollL cytosine arabinoside.
Cells subsequently were shifted into a maintenance medium that was identical to that of the plating medium but lacking fetal bovine serum. The medium was changed twice weekly. Experi ments were performed on cortical cultures after 14 to 15 days in vitro.
Slowly triggered excitotoxicity was carried out at 37°C and was induced by a 24-hour exposure to a low concentration of NMDA (12.5 fLmollL) in MS supplemented with glycine (10 fLmollL).
Neuronal cell death was estimated by examination of the cultures using phase-contrast microscopic study and measure ment of lactate dehydrogenase (LDH) released by damaged cells into the bathing medium I day after experimentation (Koh and Choi, 1987) . The LDH signal, corresponding to complete neuronal death, was determined by assaying sister cultures ex posed to 100 J-1mollL NMDA for 24 hours in MS supplemented with glycine. Background LDH levels were determined in sister cultures subjected to sham wash and subtracted from the levels in experimental conditions to yield the LDH signal specific to a given experimental injury.
Expression and purification of TbRIIs-Fc
The 
Competition of 125 I_TGF_,H binding on MvlLu cells by T�RIIs-Fc
The Mvl Lu cell line (American Type culture collection CCL-64) was maintained in Eagle's minimal essential medium supplemented with 10% fetal calf serum (Life Technologies).
The 1251_ TGFf3 1 (NEN, Life Sciences Products, Les Dlis, France) binding to monolayer cells was performed according to published procedures (Massague J, 1987) . For the competition binding assay, the final concentration of radiolabeled ligand was 40 pmollL (specific activity 3000 to 4500 Ci/mmol), with TbRIIs-Fc final concentration ranging from 0.00 1 to 10 mg/mL.
Semiquantitative reverse transcriptase polymerase chain reaction
Total RNA samples were prepared from cerebral cortex by a phenol/chloroform extraction method using the RNA Ble ex with serial dilutions of the Tf3Rlls-Fc receptor. These mixtures were added without prior incubation to the cell dishes. Binding of 12sl-labeled TGF-f31 to the cell membranes was estimated as described in the methods section and is expressed as the mean ± SD of triplicates from a representative experiment.
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30 seconds at 55°C, and 1 minute at n°e. Amplified products were separated by agarose gel electrophoresis and visualized by ethidium bromide staining.
In vivo procedures
All experiments were performed on male Sprague-Dawley rats weighing 280 to 320 g provided from CERJ (France).
Anesthesia was induced by halothane at 4% and maintained at 1 % to 1.5% administrated through a vaporizer in a gas mixture of 30% O2 to 70% N20.
Excitotoxic lesions
Rats received a unilateral injection into the left striatum: hours, rats were killed, and the brains were removed and frozen in isopentane for histologic analysis.
Middle cerebral artery occlusion
All of the rats used for the ischemia procedure were intu bated, and a femoral artery was cannulated for continuous ar terial pressure monitoring and gas analysis. Body temperature was maintained at 37.5° ± 0.2°C with a heating pad. Thirty 
Histologic analysis
Twenty-four hours after the beginning of surgery, euthanasia was performed by vertebral dislocation; the brains were rapidly removed, frozen in isopentane at -50°C, and stored at -80°e.
Cryostat-cut coronal brain sections (20 f.Lm) were stained with thionine and analyzed using an image analyzer. The lesioned areas were delimited by the paleness of histologic staining in altered tissue compared with the color of healthy tissue. Re gions of interest were determined through the use of a stereo taxic atlas for the rat (Paxinos and Watson, 1982) , and an image analysis system (BIOCOM RAG 200, Paris, France) was used to measure the lesioned area.
RESULTS
The soluble TGF-13 type II receptor prevents the in teraction of TGF-13 with its endogenous receptors.
J Cereb Blood Flow Metab, Vol. 19, No. 12, 1999 Transforming growth factor-13 type I and type II re ceptors form a ligand-dependent heteromeric signaling complex, in which the TGF-13 type II receptor tends to act as the primary and necessary receptor. In the current study, we used the extracellular domain of the TGF-13 type II receptor fused with the Fc region of a human immunoglobulin (TI3RIIs-Fc) as a soluble TGF-13 an tagonist. The TI3RIIs-Fc is a product with a molecular mass around 45 to 65 kDa, which corresponds to the purified recombinant protein. Electrophoresis analysis performed without reducing agent showed a product of molecular mass around 90 to 130 kDa, corresponding to the homodimeric form associated through its Fc domains (Komesli et ai., 1998) , To produce this molecular con struct on a large scale, CRO cells were stably transfected with the modified expression vector, pIg-Tail, containing the cDNA encoding the truncated TGF-13 type II receptor (amino acid residues 1 to 159) and a cassette for hygro mycin resistance, as described in Fig. 1A . After one-step purification by affinity chromatography on protein-A sepharose, a pure soluble chimeric protein was recovered from the culture media of CRO cells. Western blot analy sis showed that the purified recombinant protein was recognized both by a polyclonal antibody raised against the extracellular domain of TI3RII and a polyclonal an tibody faised against the human Fc fragment (data not shown). To characterize the antagonistic activity of re combinant chimeric TI3RIIs-Fc, we performed a binding experiment between membrane-bound 125 1-labeled TGF-131 and serial dilutions of TI3RIIs-Fc (0.001 to 10 mg) in mink lung epithelial cells, a cell line that expresses both TGF-13 receptors on its cell surface (Massague et ai., 1994) (Fig. 1B) . As shown in the Fig. 1B , the addition of increasing concentrations of TI3RIIs-Fc was able to counteract the binding of 125 1-labeled TGF-13 to its re ceptors (CI-50 of 0. 1 /-Lg/mL),
In vitro, the neuroprotective effect of TGF-131 against NMDA-induced necrosis is prevented by a soluble TGF-13 type II receptor.
First, we tested the influence of TGF-131 on various types of excitoxic stress thought to mimic the overstim ulation of the postsynaptic glutamate receptors observed in hypoxic-ischemic insults. We used the following glu tamatergic agonists: NMDA, AMP A, and kainate (Choi et aI., 1992) . The exposure of mixed cortical neuron-glia cultures (days in vitro 14) to these agonists produced an acute swelling of neuronal bodies followed 24 hours later by widespread neuronal degeneration, whereas the glia remained intact. The TGF-131 (l ng/mL) selectively re duced the NMDA-induced necrosis, whereas it had no effect on either AMPA-or kainate-mediated toxicity (Table 1) .
We then tested the antagonistic activity of TI3RIIs-Fc on TGF-I3I-induced neuroprotection. When neurons were exposed to NMDA (12.5 /-LmollL) for 24 hours, 80% of the cells were killed. The addition of TGF-� 1 induced a dose-dependent decrease in neuronal cell death (Table 1) . This neuroprotective effect induced by TGF-� I was abolished by T�RIIs-Fc (I [Lg/mL). The TbRIIsFc alone failed to exert any deleterious effect (Fig. 2) .
Overexpression of TGF-f31 mRNA after intrastriatal injection of NMDA Total RNA samples (I [Lg) from rat striatum were harvested and submitted to reverse transcription using poly-dT oligonucleotides. Then, 1 [LL (one twentieth) of each cDNA sample was amplified by PCR using oligo- Cell death (percent) is estimated by lac tate dehydrogenase (LDH) release (mean ± SD, n = 12) in mixed cultures either under control conditions or after a 24-hour expo sure to 12.5 �mol/L of NMDA with or without 1 ng/mL of TGF-j31, which was or was not coincubated with the soluble TGF-j3 type II receptor (1 �g/mL) (shaded columns). Asterisk indicates values significantly different from NMDA alone or TGF-j31 alone, respec tively, by one-way analysis of variance followed by Student Newman-Keuls test for multiple comparisons (P < 0.05).
nucleotides for TGF-� 1 and �-actin studied under the same conditions of amplification. Each set of oligonu cleotides gave the product of the expected size (318 bp for TGF-� l and 539 bp for �-actin). To further clarify the specificity of the PCR products, digest controls through the use of the internal restriction sites of our expected PCR products were performed (data not shown). All of our PCR reactions showed the same level of expression of the chosen housekeeping gene (�-actin) (Fig. 3) . Furthermore, a PCR control using �-actin specific primers was performed with a representative RNA sample harvested from cerebral cortices of mice to rule out any genomic DNA (data not shown). Total mRNA samples were harvested from both ipsi lateral and contralateral striata 24 hours after the injec tion of NMDA. As observed in Fig. 3 , the expression of TGF-� l mRNA was clearly enhanced as early as 6 hours and maintained until 24 hours in the striatum subjected to the NMDA injection.
TGF-f3 antagonist potentiates the NMDA-induced necrosis in vivo
To investigate the influence of TGF-� 1 produced in response to an NMDA-induced necrosis, we performed a coinjection of NMDA with either recombinant TGF-� I or T�RIIs-Fc in the rat striatum. The NMDA alone (75 nmol in 3 [LL of phosphate-buffered saline) induced a highly reproducible lesion, which was measured 24 hours later (27 ± 7 mm 3 , mean ± SD, n = 8). Coadmin istration of the recombinant human TGF-�I (3 ng) with NMDA reduced the lesion volume by 42%, thus con firming the beneficial influence observed in vitro for TGF-�l against NMDA-induced necrosis (15.7 ± 4.5 mm 3 , mean ± SD, n = 8, P < 0.005).
Moreover, when we co injected NMDA and T�RIIs-Fc (1.5 [Lg in 3 [LL), the excitotoxic lesion volume was increased by 90% (51.4 ± 11.3 mm 3 , mean ± SD, n = 8, P < 0.001) (Fig. 4) .
To rule out the possibility that the effect observed in the presence of the soluble T�RIl receptor could result from the Fc fragment of human immunoglobulin, we p-actin 
injected NMDA in the presence of 1.5 f.1g of the whole human immunoglobulin (IgG). The IgG did not modify the extent of the lesion. Similarly, the soluble TI3RII receptor alone produced only a discrete lesion (4.1 ± 0.5 mm 3 , meand SD, n = 4) (data not shown).
Overexpression of TGF-rn mRNA after transient middle cerebral artery occlusion
The interruption of cerebral perfusion that provokes stroke initiates a cascade of changes in the extracellular compartment of the brain. Here, we demonstrate modi fications in the level of expression of TGF-131 mRNA after a 30-minute transient focal ischemia induced by MCAO in the rat (Fig. 5 ). Total RNA samples from Effect of an intracortical injection of the soluble TPRII receptor on the extent of infarction induced by a reversible focal ischemia A 30-minute occlusion of the middle cerebral artery induces a highly reproducible infarction affecting both the cortex and the striatum. When we injected into the cortex 3f.1L of vehicle (phosphate-buffered solution) 30 minutes before transient occlusion of the middle cerebral artery, we measured a total infarcted volume of 43.3 ± 9.5 mm 3 (n = 6). The lesion was primarily striatal (30.2 ± 10.5 mm 3 , mean ± SD), whereas the cortical lesion was more limited (7.7 ± 29.4 mm 3 , mean ± SD). The intra cortical injection of TI3RIIs-Fc markedly potentiated the total volume of the ischemic lesion (152.8 ± 46.3 mm 3 , mean ± SD, n = 6, P < 0.0001), whereas the injection of the soluble TI3RII receptor in the absence of the ischemic insult induced only a small lesion (2.0 ± 0.5 mm 3 , mean ± SD, n = 3). This exacerbation induced by the soluble type II receptor for TGF-f:, was exclusively localized in the cortex (109.9 ± 32.3 mm 3 , mean ± SD, P < 0.0001), since there was no difference in the striatal lesion (Fig.  6 ). During these experiments, arterial pressure, pH, P0 2 and Peo 2 pressure were monitored. There was no differ ences in the physiologic parameters between the two experimental groups (Table 2) .
DISCUSSION
In the current study, we demonstrate that the expres sion of the mRNA for TGF-f:,l increases after an exci totoxicity-induced or an ischemia-induced brain lesion. The observation that the expression of the mRNA for TGF-f:,1 is dramatically enhanced after brain injury is consistent with previous studies (Prehn et aI., 1993; Vivien et aI., 1998) . However, to exert its biological activity, the protein TGF-f:,1 needs to be activated. In fact, TGF-f:, 1 is secreted in a latent form made of a TGF-f:, 1 active dimer associated with a set of proteins (Harpel et aI., 1992; Souchelnitsky et aI., 1995) . The activation of this complex is an essential step for this cytokine to exert its activity (Wrana et a!., 1994 and . Thus, the presence of high levels of mRNA does not predict the implication of this cytokine in the outcome of the injury. To investigate the role of active TGF-f:, 1, it was necessary to antagonize its bio logical action. Since there is no synthetic and selective antagonist available, we developed a soluble TGF-f:, type II receptor that was characterized for its ability to prevent the interaction of TGF-f:, with its native receptors. First, we studied the influence of this soluble receptor in a model of excitotoxicity in cortical murine cultures. We confirm previous observations that TGF-131 reduces the neuronal death induced by NMDA (Prehn et aI., 1993; Henrich-Noack et aI., 1996) . Moreover, the neuroprotec tive effect of TGF-f:, 1 is reversed by the soluble Tf:,RII receptor, thus validating the functional antagonist prop erty of this construct on TGF-f:,1 signaling.
The core investigation of this study was to determine the effect of Tf:,RIIs-Fc on an excitotoxic lesion induced by the intrastriatal injection of NMDA in rats. Recom binant TGF-f:,1 reduces the NMDA-induced lesion size by 40% and would thus support the neuroprotective ef fect observed in vitro. Soluble Tf:,RII provokes an in crease of the NMDA-induced lesion by 92%. Even if injection of the soluble receptor TbRIIs-Fc alone induces a small lesion, the increase in the lesion size observed cannot be explained by simple additive effects. Thus, these results demonstrate that a cerebral tissue exposed to an excitotoxic stress is able to produce a cytokine that limits the extent of the injury.
Excitotoxicity may contribute in an important manner to several forms of acute injury to the nervous system, including stroke. Accordingly, it was thought essential to evaluate the influence of TGF-f:,1 in an experimental model of cerebral ischemia. By injecting the Tf:,RIIs-Fc into the cortex 30 minutes before the induction of a re versible focal cerebral ischemia, we were able to selec tively block the influence of endogenously produced TGF-f:,1 in this structure. This strategy resulted in a dra matic enhancement of the volume of damaged cortical tissue. These findings indicate that the activation of TGF-f:, receptors modulates NMDA-induced neuronal cell death both in vitro and in vivo.
The role of TGF-f:, in brain diseases has not been adequately resolved. This cytokine has been proposed to exert antiapoptotic effects in vitro (McNeill et aI., 1994; Henrich-Noack et aI., 1996) and to modulate astrocytic reactivity (Lindholm et aI., 1992) , both of which might suggest a possible direct or indirect effect of TGF-f:, on the survival of neurons. In addition, this factor is in volved in the deposition of the extracellular matrix (Westerhausen et aI., 1991) and thus increases wound healing. Also, TGF-f:, may be involved in antiinflamma tory processes (Kulkarni et aI., 1993 , McNeill et aI., 1994 . Although Prehn et al. (1993) describe that the intracerebroventricular injection of recombinant TGF-f:, 1 induces a slight reduction in infarct size after cerebral focal ischemia in mice, no clear evidence of a role for endogenous TGF-[3 has been proposed. The major find ing of the current experiments is that an intrastriatal in jection of a recombinant antagonist for TGF-[3, T[3RIIs Fc, dramatically enhances an NMDA-induced lesion. This observation is the first demonstration that a cyto kine, produced in response to an excitotoxic stimulus, exerts a neuroprotective activity. This result is strength ened by the beneficial activity of exogenously applied TGF-[3, observed in vivo, against NMDA-induced lesion. These data strongly indicate that the activation of the TGF-[3 signaling pathway initiates a cascade of events beneficial for brain tissue exposed to an excitotoxic stress. The early activation of this pathway or its ampli fication might represent a novel therapeutic approach for the treatme f\ t of acute brain injury. However, the mo lecular mechanisms underlie the neuroprotective effect of TGF-[31 in vivo remain to be elucidated. Previously, we demonstrated in vitro that TGF-[31 may exert its neu roprotective effect by upregulating a protein synthesized by astrocytes: the plasminogen activator inhibitor-}, a protein characterized by its ability to inhibit tissue-type plasminogen activator activity (Inagaki et aI., 1994) . How might tissue-type plasminogen activator be in volved in excitotoxic injury? The question remains un resolved, but experimental data obtained from tissue type plasminogen activator knock-out mice reveal that such animals are relatively resistant to an excitotoxic stress (Tsirka et aI., 1997) and to ischemia (Wang et aI., 1998) . Finally, the current study validates the use of recombinant soluble receptors as a powerful tool to in vestigate the role of cytokines in vivo. A better knowl edge of the influence of various cytokines, including TGF-[3 produced by injured tissue after cerebral isch emia, may promote several innovative therapeutic ap proaches.
